Supplementary Methods, Supplementary Figures 1-10, Supplementary References from CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors

Figure S1. PTCs with BRAFV600E mutations are associated with ICAM-1 Overexpression; Figure S2. Tumor tissue morphology in ATC patients.; Figure S3. ICAM-1-overexpressing ATC cell lines are more proliferative.; Figure S4. ICAM-1 CAR T cell phenotype characterization; Figure S5. Validation of ICAM-1 CAR T cells used in vivo experiments.; Figure S6. Organ weight changes in ATC xenografted mice after ICAM-1 CAR T treatment.; Figure S7. CAR T cells in ICAM-1 CAR T treated and ATC xenografts.; Figure S8. Establishment of ATC patient-derived xenografts.; Figure S9. CAR T activity is detectable throughout the body.; Figure S10. Correlation between ICAM-1 overexpression in TCGA cancer patient tumor tissues and overall survival.